| Next 10 |
Ad
DTIL News and Press Precision BioSciences Inc.
News | Precision BioSciences Inc. (NASDAQ:DTIL)
- DTIL - Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will prese...
-
2025-03-26 07:03:40 ET More on Precision BioSciences Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel Precision BioSciences Q4 2024 Earnings Preview Precision Bio gains on early Phase 1 data for Hep B candidate Seeking Alpha&#...
-
Nu Ride Inc. - Class A (NRDE) is expected to report for quarter end 2024-12-31 Dalrada Financial Corp. (DFCO) is expected to report for quarter end 2024-12-31 HilleVax Inc. (HLVX) is expected to report $-0.38 for Q4 2024 Chewy Inc. Class A (CHWY) is expected to report $0.03 for Q4 202...
-
2025-03-25 18:00:00 ET Major earnings expected before the bell on Wednesday include: Chewy ( CHWY ) Cintas ( CTAS ) Dollar Tree ( DLTR ) JinkoSolar Holding ( JKS ) Paychex ( PAYX ) Read the full article on Seeking Alpha For further det...
-
2025-03-25 13:51:44 ET More on Precision BioSciences Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel Precision Bio gains on early Phase 1 data for Hep B candidate Precision Bio rises after gene editing data: BMO upgrades (update) ...
- DTIL - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financ...
-
2025-03-15 08:42:25 ET Summary Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI ach...
-
2025-02-24 07:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that the company will present p...
-
2025-02-19 07:53:44 ET More on Precision BioSciences Precision Bio rises after gene editing data: BMO upgrades (update) Seeking Alpha’s Quant Rating on Precision BioSciences Historical earnings data for Precision BioSciences Financial information for P...
Stock Information
Get DTIL Alerts
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NASDAQ Market:
0.18% G/L:
$5.33 Last:
69,382 Volume:
$5.49 Open:
$5.33 Close:
Precision BioSciences Inc. Website:
Ad
- DTIL - Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will prese...
-
Nu Ride Inc. - Class A (NRDE) is expected to report for quarter end 2024-12-31 Dalrada Financial Corp. (DFCO) is expected to report for quarter end 2024-12-31 HilleVax Inc. (HLVX) is expected to report $-0.38 for Q4 2024 Chewy Inc. Class A (CHWY) is expected to report $0.03 for Q4 202...
- DTIL - Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financ...